Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

RVNC

Revance Therapeutics Inc

Dec 11 • 04:00PM ET

3.04

Dollar change +0.01
Percentage change 0.50	%

Healthcare • Biotechnology • USA • NASD

Peers: MRK NBIX ZTS PRGO EOLS CTMX SRTS LFVN PDSB VSTM

| Held by: VTI IWM VXF IWO VTWO VHT IBB SCHA MNA ARB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.92	Insider Own	8.77%	Shs Outstand	104.90M	Perf Week	-27.10%
Market Cap	317.35M	Forward P/E	-	EPS next Y	-0.69	Insider Trans	-0.04%	Shs Float	95.76M	Perf Month	-11.88%
Income	-184.44M	PEG	-	EPS next Q	-0.25	Inst Own	80.34%	Short Float	13.27%	Perf Quarter	-53.66%
Sales	247.00M	P/S	1.28	EPS this Y	42.40%	Inst Trans	-4.06%	Short Ratio	3.98	Perf Half Y	0.50%
Book/sh	-1.55	P/B	-	EPS next Y	38.87%	ROA	-36.38%	Short Interest	12.70M	Perf Year	-58.97%
Cash/sh	1.77	P/C	1.72	EPS next 5Y	11.60%	ROE	-2096.78%	52W Range	2.30 - 9.74	Perf YTD	-65.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	0.57%	ROI	-62.94%	52W High	-68.80%	Beta	0.84
Dividend TTM	-	Quick Ratio	3.05	Sales past 5Y	815.27%	Gross Margin	70.15%	52W Low	32.17%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	4.12	EPS Y/Y TTM	61.49%	Oper. Margin	-67.21%	RSI (14)	31.61	Volatility	3.58% 6.82%
Employees	597	Debt/Eq	-	Sales Y/Y TTM	15.33%	Profit Margin	-74.67%	Recom	3.00	Target Price	5.16
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	77.56%	Payout	-	Rel Volume	0.86	Prev Close	3.03
Sales Surprise	-12.17%	EPS Surprise	-37.55%	Sales Q/Q	5.47%	Earnings	Nov 07 AMC	Avg Volume	3.19M	Price	3.04
SMA20	-19.71%	SMA50	-34.94%	SMA200	-32.17%	Trades		Volume	2,736,343	Change	0.50%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Downgrade	Mizuho	Buy → Neutral	$16 → $9
Jan-09-24	Downgrade	Goldman	Buy → Neutral	$30 → $8
Aug-16-23	Upgrade	Exane BNP Paribas	Underperform → Neutral	$20
Oct-11-22	Initiated	Morgan Stanley	Equal-Weight	$27
Sep-22-22	Initiated	Goldman	Buy	$33
Oct-25-21	Downgrade	Wells Fargo	Overweight → Equal Weight	$35 → $17
Oct-15-20	Reiterated	Needham	Buy	$36 → $42
Aug-11-20	Resumed	Mizuho	Buy	$32
Mar-23-20	Downgrade	Goldman	Buy → Neutral	$32 → $15
Dec-02-19	Initiated	Goldman	Buy
Oct-30-19	Upgrade	Wells Fargo	Market Perform → Outperform	$20
Jun-11-19	Initiated	Barclays	Overweight	$28
Feb-15-19	Initiated	Wells Fargo	Market Perform
Feb-14-19	Initiated	H.C. Wainwright	Buy	$25
Jan-29-19	Initiated	Stifel	Buy	$50
Nov-16-18	Upgrade	Guggenheim	Neutral → Buy
Sep-17-18	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Apr-20-18	Reiterated	Mizuho	Buy	$54 → $48
Mar-27-18	Initiated	Needham	Buy	$42
Mar-05-18	Initiated	Goldman	Buy	$60

Show Previous Ratings

Dec-09-24 09:12AM	Revance agrees to lower take-private offer by Crown Labs (Reuters) -20.68%
08:30AM	Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement (PR Newswire)
Nov-07-24 06:20PM	Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -35.99%
04:05PM	Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update (Business Wire)
Sep-27-24 09:35AM	Down -17.96% in 4 Weeks, Here's Why Revance Therapeutics (RVNC) Looks Ripe for a Turnaround (Zacks)
01:14AM	Loading…
Sep-17-24 01:14AM	Beryl Capital Management LLC Acquires New Stake in Revance Therapeutics Inc (GuruFocus.com)
Sep-12-24 01:12AM	Capital World Investors Reduces Stake in Revance Therapeutics (GuruFocus.com)
Aug-29-24 09:55AM	How Much Upside is Left in Revance Therapeutics (RVNC)? Wall Street Analysts Think 55.02% (Zacks)
Aug-13-24 09:55AM	Can Revance Therapeutics (RVNC) Climb 98.64% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-12-24 09:27AM	Crown Laboratories, Revance Enter Merger Agreement (Exec Edge) +86.97%
08:15AM	Botox rival Revance to go private in $924 million deal (Reuters)
08:00AM	Crown Laboratories and Revance Announce Entry Into Merger Agreement (PR Newswire)
Aug-08-24 06:00PM	Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +19.66%
04:05PM	Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update (Business Wire)
Aug-01-24 04:05PM	Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (Business Wire) -10.85% -5.04%
06:00AM	Loading…
Jul-11-24 06:00AM	Stocks to Buy: 3 Breakout Stars to Transform Your Portfolio (InvestorPlace) +12.37%
Jun-14-24 04:05PM	Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.05%
May-28-24 04:05PM	Revance to Participate in Upcoming Investor Conferences (Business Wire)
May-24-24 09:35AM	Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-22-24 08:50PM	The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains (InvestorPlace) -8.56%
May-12-24 04:00PM	3 Underappreciated Stocks That Could 10x in 10 Years (InvestorPlace)
May-10-24 04:30PM	Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2024 Earnings Call Transcript (Insider Monkey) -22.61%
03:04PM	Revance Therapeutics Reports Q1 2024 Financial Results: Revenue Growth Amidst Rising Operating ... (GuruFocus.com)
11:36AM	Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating (MT Newswires)
10:20AM	Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating (MT Newswires)
May-09-24 06:25PM	Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:06PM	Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update (Business Wire)
04:05PM	Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia (Business Wire)
May-02-24 04:05PM	Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024 (Business Wire)
Apr-12-24 08:00AM	Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting (Business Wire) -6.98%
04:05PM	Loading…
Mar-27-24 04:05PM	Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.11%
Mar-04-24 09:25AM	Revance Announces Pricing of $100.0 Million Public Offering of Common Stock (Business Wire) -13.04%
06:37AM	Revance Announces Proposed Public Offering of Common Stock (Business Wire)
Mar-02-24 08:23AM	Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 06:41AM	Q4 2023 Revance Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +26.15%
Feb-28-24 04:43PM	Revance Therapeutics Inc (RVNC) Reports Strong Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update (Business Wire)
Feb-21-24 08:01AM	Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024 (Business Wire)
08:00AM	Revance to Participate in Upcoming Investor Conferences (Business Wire)
Feb-02-24 08:00AM	Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology® (Business Wire)
Feb-01-24 08:00AM	Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference (Business Wire)
Jan-08-24 08:00AM	Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook (Business Wire) -15.57%
Nov-09-23 07:05PM	Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Call Transcript (Insider Monkey) -17.05% -13.60%
09:54AM	Q3 2023 Revance Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 07:00PM	Revance Therapeutics, Inc. (RVNC) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
04:06PM	Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update (Business Wire)
04:05PM	Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics (Business Wire)
Nov-06-23 08:00AM	Revance to Participate in Upcoming Investor Conferences (Business Wire)
Nov-01-23 08:00AM	Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 (Business Wire)
Oct-26-23 08:00AM	DAXXIFY® Becomes First Facial Injectable to be Named to TIMEs Best Inventions (Business Wire)
Oct-14-23 01:15PM	13 Stocks to Buy with Exponential Growth (Insider Monkey)
Sep-19-23 04:18PM	Former IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke (Investor's Business Daily) -17.31%
09:00AM	Revance Provides Corporate Update at Investor Day (Business Wire)
Sep-06-23 02:27PM	3 Healthcare Stocks to Sell in September Before They Crash & Burn (InvestorPlace)
12:43PM	Revance Therapeutics (RVNC): A Smart Investment or a Value Trap? An In-Depth Exploration (GuruFocus.com)
Aug-29-23 12:43AM	3 Very Oversold Biotech Stocks to Buy Right Now (InvestorPlace)
Aug-22-23 10:43AM	Load Up, Says Goldman Sachs About These 2 Strong Buy Stocks (TipRanks)
08:00AM	Revance to Host Investor Day on September 19, 2023 (Business Wire)
Aug-21-23 04:09AM	Revance Therapeutics (RVNC) Shares Declined on Profit-Taking (Insider Monkey)
Aug-14-23 04:03PM	How Revance Is Taking A Page Out Of AbbVie's Botox Playbook (Investor's Business Daily)
08:00AM	U.S. FDA Approves First Therapeutic Indication for Revances DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia (Business Wire)
Aug-08-23 06:15PM	Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.05%
04:05PM	Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update (Business Wire)
Aug-03-23 09:19AM	Swelling losses haven't held back gains for Revance Therapeutics (NASDAQ:RVNC) shareholders since they're up 23% over 1 year (Simply Wall St.)
Aug-01-23 08:00AM	Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (Business Wire)
Jul-29-23 11:39AM	10 Oversold Biotech Stocks to Buy (Insider Monkey)
Jul-13-23 03:00PM	10 Best Revenue Growth Stocks to Buy (Insider Monkey)
09:35AM	After Plunging -17.93% in 4 Weeks, Here's Why the Trend Might Reverse for Revance Therapeutics, Inc. (RVNC) (Zacks)
Jun-29-23 06:20AM	Reata Pharmaceuticals, Inc. (RETA) Moves 7.0% Higher: Will This Strength Last? (Zacks)
Jun-21-23 08:41PM	7 Healthcare Stocks to Make You the Millionaire Next Door (InvestorPlace)
May-23-23 04:05PM	Revance to Participate in Upcoming Investor Conferences (Business Wire)
May-17-23 06:35AM	Daily Vickers Top Buyers & Sellers for 05/17/2023 (Argus Research)
May-16-23 02:34AM	Heres Why Revance Therapeutics (RVNC) Outperformed in Q1 (Insider Monkey)
May-10-23 10:45AM	This Botox Rival Has Investors Frowning After Missing Q1 Earnings Estimates. The Stock Reversed Course After The Report. (Investor's Business Daily)
May-09-23 06:05PM	Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update (Business Wire)
06:25AM	Top 4 Stocks Set to Beat on Earnings Today After Market Closes (Zacks)
May-02-23 10:01AM	Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
08:00AM	Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023 (Business Wire)
Apr-18-23 08:41AM	Revance Therapeutics, Inc.'s (NASDAQ:RVNC) P/S Is On The Mark (Simply Wall St.)
Apr-05-23 08:00AM	Revance to Participate in the Needham 22nd Annual Healthcare Conference (Business Wire)
Apr-04-23 11:15PM	7 Stocks to Buy for the Massive Rally Ahead (InvestorPlace)
Mar-30-23 08:00AM	Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report (Business Wire)
Mar-29-23 05:36AM	Intra-Cellular (ITCI) Surges 16.4%: Is This an Indication of Further Gains? (Zacks)
Mar-07-23 08:00AM	Revance to Participate in Upcoming Investor Conferences (Business Wire)
Mar-03-23 08:11PM	Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-01-23 10:33AM	Q4 2022 Revance Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -7.06%
Feb-28-23 07:45PM	Revance Therapeutics, Inc. (RVNC) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:06PM	Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update (Business Wire)
04:05PM	Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director (Business Wire)
Feb-27-23 08:00AM	Revance to Participate in the 43rd Annual Cowen Healthcare Conference (Business Wire)
06:21AM	Reasons for the Decline of Revance Therapeutics (RVNC) in Q4 (Insider Monkey)
Feb-24-23 05:10PM	Why Unprofitable Stocks Make The IBD 50; Here's How 4 Earn Their Place (Investor's Business Daily)
07:48AM	Revance Therapeutics (NASDAQ:RVNC) shareholders have earned a 154% return over the last year (Simply Wall St.)
Feb-23-23 08:00AM	Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting (Business Wire)
Feb-22-23 10:00AM	Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-21-23 04:05PM	Revance to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023 (Business Wire)
Feb-20-23 10:00AM	Earnings Preview: Revance Therapeutics, Inc. (RVNC) Q4 Earnings Expected to Decline (Zacks)
Feb-03-23 02:15PM	How Revance Therapeutics, The IBD 50's No. 1 Stock, Is Taking On 'Prestige' Medical Aesthetics (Investor's Business Daily)
Feb-02-23 12:00PM	What Makes Revance Therapeutics, Inc. (RVNC) a Strong Momentum Stock: Buy Now? (Zacks)

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hollander David	CMO & Global Therapeutics Lead	Nov 18 '24	Sale	4.17	3,908	16,296	104,945	Nov 19 04:31 PM
Jordan Erica	Chief Commercial Officer	Apr 16 '24	Sale	3.80	2,392	9,096	114,864	Apr 17 04:34 PM
Sjuts Dustin S	President	Mar 18 '24	Sale	5.04	9,211	46,446	167,550	Mar 19 06:45 PM
Moxie Dwight	CLO & GC	Mar 18 '24	Sale	5.04	8,125	40,971	137,815	Mar 19 06:44 PM
Schilke Tobin	CFO	Mar 18 '24	Sale	5.04	9,361	47,204	192,666	Mar 19 06:44 PM
Foley Mark J	CEO	Mar 06 '24	Buy	6.98	30,000	209,400	1,015,468	Mar 08 04:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RVNC

Revance Therapeutics Inc

Upgrade your FINVIZ experience